RespireRx Pharmaceuticals Inc (CE) (RSPI) 시세

Interesting deal in that Lilly is acquiring an asset while scorpion is spinning out everything else to a new company…

Similar as RSPI is spinning assets into EndeavourRX. I am just wondering which assets are going into EndeavourRX. And will BP jump on licensing or owning the pain candidate as it exits IND enabling?

How is the deal done? In my one buyout it was all about one stupid little patented compounded drug formula that some Japanese company made an offer on after a long and pronounced period of suffering thru lower share prices. This was mostly due to the company financing a large loan sum towards the end that did not make any sense to the shareholders. It didn't smell right to me, so I averaged down a lot and hung on. Months later, the offer was made (which I believe was around 14 Dollars) and the stock price opened right there (minus a few pennies) so the MMs could make a few pennies buying from anyone who wanted to sell before the deal closed. I did not sell because I was hoping for a competing offer (bidding war) but that did not materialize. After the deal closed, maybe 4 or 6 weeks later, the transfer occurred, the symbol disappeared, and the proceeds went to my account's cash balance. Turns out the buyers had demanded cash as part of the deal and that's why the seller took out the crazy large loan with no explanation. The company couldn't say anything about the loan and that was a tipoff for me. Many sold around $1.50 because of that loan. Just one of the multitude of twists that can befall someone holding long. I'm hoping the EM thing here is just another of these tactics.

So in a merger/acquisition where they say they pay 7.22$ per share, for example, how does that work for the existing shareholders? How is the deal done? What happens in the shareholders’ accounts? That never happened to one of my stocks.

Looking good , I would love 7.22 a share here. GLTA

Look at Scorpion Therapeutics - RSPI IMO has more to offer. Lilly is paying 2.5 billion!

In 2025, many biotech companies are expected to be involved in mergers and acquisitions (M&A), including:
Lantheus Holdings: Acquiring Life Molecular Imaging (LMI) for $350 million, plus potential additional payments
Johnson & Johnson: Acquiring Intra-Cellular Therapies
Eli Lilly: Acquiring Scorpion Therapeutics for $2.5 billion
GlaxoSmithKline (GSK): Acquiring IDRx
Salarius Pharmaceuticals: Merging with Decoy Therapeutics
Biogen: Acquiring Sage Therapeutics for $7.22 per share
Vividion Therapeutics: Acquiring Tavros Therapeutics

I need a much bigger green lantern for this thing! LOL

Looks like I'm a little high on the estimate. We want OTCID + the Application fee = $11,000

Attorney fee + TA fees

Needs to be in the TA Verified shares program

How did you arrive at this? "13k to OTCM "
https://www.otcmarkets.com/corporate-services/fee-schedule

"Needs TA Verified and Form 15." ....and up to date financials plus an attorney letter if they're unaudited.

How many more wishes you have left from the lantern? lol

Hopefully you can get your mystery painter to start on the next floors of this high rise. The lobby has many coats of paint on it already...

And even with that price of two and a half pennies, the market valuation would only be 25 million...

Still peanuts for a pharma with this pipeline and multiple candidates, multiple indications in large unmet markets at clinical stage..

Ditto that $$$$. Up 100%. * This ticker could open 1000 % with the right news $$.

RSPI

Whomever painted this .0024 I appreciate that from the bottom of my heart! Portfolio looks awesome at .0024 vs .0012! THANK YOU!!!

Closed .0016 x .0024

Someone tapped the ask

Seems simple enough and good thoughts. Wonder where they get this idea it cost just as much to go alternative reporting?

Seems better route and cost effective and heck maybe they spin out or IPO the subs anyhow and distribute equity down the line..

Agree 100%

Well if cost is the issue, it's best to go Alt Reporting. Pay the 13 grand to OTCM and get trading again. It would trade the same as SEC Reporting but don't need to deal with auditors and all those high expenses, usually 6 figures.

It already lost the 211, OTCM would sponsor it either way.

And a lot of reputable companies choose OTCM reporting until they get back on their feet. It can refile a Form 10 any time.

Yeah seems simple. What advantages are there to stay SEC registered? Reputation? Legitamacy? Sounds like the major funding will take place within the subsidiaries which will have their own financials.. Or do they need to have certain level of financial auditing at the licensor of technology level?

Needs TA Verified and Form 15.

13k to OTCM

Could have the greatest assets in the world, but those 2 things are the most important right now.

I would expect this to take off like it was bound too after the DOD phase 2 news, with the added benefit now that there is likely significant news related to grants, additional funding and bp partnerships all looming.. But yeah, I think they need to announce a strategy to investing public of how they anticipate getting off the EM. Do they want to drop all the filings in a day and have a mad rush bid this up several pennies on the EM? Or will they stagger the filings out and allow for a more steady accumulation/consolidation on the upward trajectory to minimize extreme volatility? Or maybe they just announce a big partnership or funding deal while on the EM with different plans for the equity and create all kinds of havoc for entities to scramble to find shares??

Well the company internally says their assets are worth 50+ million thats .05 today and that may be conservative as KRM-ll-81 exits preclincals/IND enabling for pain.

Doesn't matter, until off the EM this wont really get moving like that..

I couldn't imagine that, but sure would be welcome in my portfolio right about now.

Guarantee if fillings are dropped 1 by 1 leading into the finale day of going current all it would take is a couple of low volume hits are we will open above 006 minimum ran past 01 rather quickly 

Well if one just wants that excitement, bigt usually has some for sale at .05

Then we can really see what coulda shoulda woulda... but probably still shoulda woulda in the not too distant future, assuming they are serious about getting these candidates into clinicals under the best circumstances for success...

No problem. I read alot so the only caveat is the information is only as good as what is found on the internet and well all the A.I. jazz that now convolutes information nowdays...

Thanks for all the details it’s appreciated

GTA

Hmmm I have a bid at .0015?

Thanks for posting the bid and ask here Lime Time! It's much appreciated!

I can't argue with you as you are 100% correct including the Dopamine effect! LOL

What's the point even if 002 it's an illusion till back on the market. The price jump just deludes our senses for a brisk hit of dopamine lol

.0013 x .0024

I am assuming it's still .002 or higher?

I wish someone would just tap the ask for just 100 shares just to get us out of these .0012's and back into the .002's. Especially before the close. I would do it in a heartbeat but I cannot buy expert market stocks in the U.S. These .0012's suck in the portfolio.

From what I read they can go back and forth for months on end negotiating and such before any final determination is made to strip of SEC registration and then there is still an appeal process, etc, etc. And after all that additional embarassment they could then go alternative reporting route onto the pink market. One would think having important dealings with both DOD and NIH would add a few points to allow plenty leeway for the "management" to get their xxxx together...

It truly is unbelieveable they are at this point having investors and potential investors/partners having to concern themselves with this foolishness. Announce a plan to get off the expert market and follow through so they can get on with establishing the foundations to build out resources and partnerships needed for this significant pipeline.

"Together, we can advance life-changing therapies, create value for our investors, and positively impact the lives of patients worldwide." Looking forward to it!!

Last time I hit Jeff up , they were waiting to hear back from the SEC .

What’s happening with the revocation notice? Are we past the delay?

"They went through all that effort, going the extra mile… "

Yes. Commendable. Thoughtful. Investors seek quality in this regards and should explain why there are not many shares available at these depressed levels as stakeholders in pharma can see the progress and accomplishments and understand the potential to be breakthrough on multiple levels in multiple lanes is exciting for all...

Yet... "neglect", "stupid issue holds them back"... Why is this? Incompetance? OTC shenanigans? Poor Advisory? This is embarrassing and upsetting and there are really no excuses.....

Despite it all... "lovely little book project." we all still envision a great story stock emerging from the shadows.

Look at the bright side. No fraud, no scam, no BS.
They have real, tangible, legitimate, enforceable assets, real science, which their small core group of collaborators have fleshed out in a particularly thorough and obstinate way, such that any dirty fat fingers trying to help themselves will be named and shamed and booed.

They went through all that effort, going the extra mile… For a reason. It aligns with their values, and the foundation of their motivation, which also leads them to neglect certain things that are necessary to do well in business. Otherwise they would not be so undervalued. They would not be in that situation.
And it’s quite interesting to see that some stupid issue holds them back pretty hard. Because it says more about the system than them.
So after all is resolved and they are vindicated this will be a lovely little book project.

Why on Earth they let this go to the EM and is still on the EM is beyond me...
The shareholder letter was perfect in defining what they have going on and where they see themselves going.

Truly the picture of consistency. I don't get it.

I agree completely.

My sense is it just might be an overbooked rocket ride. The shareholder letter was perfect in defining what they have going on and where they see themselves going. And clearly some confidence (for a company on the EM) with talk of in-licensing more, acquiring assets, discussing commercial proposals, acquiring more grant funding etc, etc. Only adds to more eyes now watching here.

This lingering on the EM is compressing the timelines of possible "events" in motion... Meaning they could be looking at a series of material events incoming that will completely transform the company. And I think the due diligence and the stellar job on positioning the candidates all point to that...

Why on Earth they let this go to the EM and is still on the EM is beyond me...

I know its absolute insanity! I really can't wait to get off this expert market.

I can see that as a possibility as that company is flush with cash and growing and I believe my notes suggested they were really investing heavily in non-opioid pain research... Would love to see it.

smh a company like this with these assets and an astounding effort to position these candidate drugs to do big big things for multiple medical indications that have millions and millions of patients with unmet needs..... is stuck here on an expert market "trading" on the whims of a few bucks here and there...

ugg.

Lilly loves the small guy just for the patents. It will happen sooner than later .
.

I think they would have done it by now.

Staying EM until they are ready to unleash everything in terms of clinicals starting, financing the neuromodulator platforms and additional grant funding and NIH/BP partnerships for pain indications is really going to isolate this to the actual investors with equity positions now and any new financiers for these platforms. Peanuts to .10 or .20 has happened many times before on the OTC and this company has leaps and bounds more potential than any of those past OTC story stocks...

I wish someone would paint this back up into the .002's. I would do it myself, but we cannot buy here in the U.S.

Yeah I kinda wonder that as well. The NIH and BP and whomever may partner on AND support something as significant as KRM-ll-81 for pain is not going to want to horse around with dragging their feet with OTC shenanigans and whatever market platform it is "trading" on... Hence I have wondered if they might be considering a way off the OTC. M&A with an established NASDAQ shell or better yet some pharma that may have some cash/resources but no viable assets left due to clinical failure and such.... Feels like a much better place for this neuormodulator platform that can benefit SCI/ADHD with one platform and pain/epilepsy with the other. Huge undertaking, huge markets and extremely promising candidates!

And we'd probably get some professional websites and presentations too! All to really unlock value of these assets short, medium and long term.. Would not have to deal with penny stock flippers either as those of us left here are long and invested and really some penny stock investor looking to acquire and flip shares is limited on the EM.

Not sure if it is out the window, I just recalled that info. Maybe when he stated that it was just the start of the EM and they thought they were not going to be on it long. If someone wanted to go back that far I am pretty sure I posted it. I think they know they need to do something for the shareholders and the company to trade again. You can't expect an investor to be hyped to invest in a company on the EM. Maybe the new OTC rules is what they are waiting on to just drop all the necessary filings to enter that tier. All a guess at this point, Jeff wont say to much on the direction due to insider information just points back at the last filing for info. GLTA

This IS going to get bought by one of the big boys . JMHO but they have way to much going for them . May be a minute but it's going to happen .

So the idea of going alternative reporting is essentially out the window in your view?

Must be some major reason to spend the ridiculous amount of money to stay audited on the OTC. Or will it be OTCID by then or whatever the new term for pink is...